Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Lifeworks Advisors LLC

Lifeworks Advisors LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,155 shares of the pharmaceutical company's stock after selling 529 shares during the period. Lifeworks Advisors LLC's holdings in Vertex Pharmaceuticals were worth $1,530,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Mascagni Wealth Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth about $31,000. Mpwm Advisory Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $40,000. Minot DeBlois Advisors LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $44,000. Prestige Wealth Management Group LLC grew its stake in Vertex Pharmaceuticals by 45.5% in the fourth quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock worth $45,000 after purchasing an additional 35 shares in the last quarter. Finally, SJS Investment Consulting Inc. grew its stake in Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock worth $46,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VRTX. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price objective on Vertex Pharmaceuticals and gave the company a "sector perform" rating in a research note on Tuesday, June 17th. Bank of America lifted their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research note on Monday, March 31st. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Wolfe Research lowered Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Fourteen analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $512.30.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX traded down $2.62 during mid-day trading on Friday, reaching $469.65. The stock had a trading volume of 1,176,853 shares, compared to its average volume of 1,076,910. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The firm has a market capitalization of $120.61 billion, a price-to-earnings ratio of -119.81 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The business has a 50 day simple moving average of $453.13 and a 200 day simple moving average of $464.68.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the previous year, the business posted $4.76 earnings per share. Vertex Pharmaceuticals's revenue was up 2.6% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.